Group With Ties to Trump Opioid Chief Scores Big

opioid crisis

The Trump administration has awarded $24 million in grants to a small New England nonprofit group with ties to President Donald Trump’s opioid czar, Assistant Secretary for Mental Health and Substance Use in the Department of Health and Human Services — Elinore F. McCance-Katz — a WhoWhatWhy review of government documents reveals.

The American Academy of Addiction Psychiatry (AAAP), based in East Providence, RI, has been awarded $12 million per year for each of the next two years — the largest government grant the AAAP has ever received, an analysis of government records shows. AAAP will be paid to provide technical assistance for programs designed to help states cope with the opioid epidemic.

The grant comes through the Substance Abuse and Mental Health Services Administration (SAMHSA), an agency run by McCance-Katz. She is the AAAP’s former president, one of its 26 distinguished fellows, and was, until recently, an associate editor of its in-house journal.

The grant also comes at a time when McCance-Katz is slashing spending to other outside providers as part of a decades-long struggle over differing approaches to mental health. The AAAP approach is the “medical model” of mental health. (See below). It leaves AAAP as one of the few technical advisers standing. And, because AAAP’s role comes through a grant, it cannot be appealed in the same way as a contract award might be.

In a statement sent through her agency’s spokesman, McCance-Katz rejected any suggestion that she had influenced the grant decision.

“I had no role in the selection or awarding process,” the statement read. “I went so far as to decline meeting with AAAP and other organizations that potentially could have interests pursuing the grant opportunity.”

‘American Carnage’

.

Opioid abuse and addiction have arguably become America’s worst public health crisis since the early days of the AIDS epidemic. Every day, nearly 115 people die from an overdose, according to federal statistics. Nearly 50,000 Americans died from opioid overdoses last year. That’s almost as many Americans as were killed in a decade of war in Vietnam.

opioid overdoses

Quarterly rate of suspected opioid overdoses, by US region. Photo credit: CDC / Drugabuse.gov

The opioid crisis is also an issue that the Trump administration cannot afford to mess up. The president’s “American carnage” rhetoric was aimed at the epidemic’s victims — at least one 2016 study found that Trump’s biggest support came from places most stricken by opioids.

The nomination of McCance-Katz was taken by many — including some critics — as a rare sign of seriousness by the administration.

Medical v. Recovery

.

A psychiatrist trained at the University of Connecticut and Yale, McCance-Katz has spent most of her adult life treating addiction. From 2013 to 2015, she was the first full-time chief medical officer at SAMHSA. She is now the first person ever appointed assistant secretary for Mental Health and Substance Use at the Department of Health and Human Services, a near-Cabinet-level job created by Congress in part to respond to the opioid crisis.

McCance-Katz has been a champion of the so-called “medical model” of mental health — where the emphasis is on medicating and even hospitalizing people with mental illness or addiction.

Her appointment raised concerns among other practitioners who support what is known as the “recovery model,” addiction treatment that emphasizes more community supports — like job-training and placement — and strengthening family ties.

McCance-Katz announced her intentions in a statement posted on SAMHSA’s website on January 11. She criticized “practices and programs submitted by outside developers,” that she said had created “a skewed presentation of evidence-based interventions” that “did not address the spectrum of needs of those living with serious mental illness and substance use disorders.”

Instead, her agency would redirect funds so that it could offer “targeted technical assistance and training that makes use of local and national experts and that assist programs with actually implementing services that will be essential to getting Americans living with these disorders the care and treatment and recovery services that they need.”

Elinore McCance-Katz

Assistant Secretary for Mental Health and Substance Use Elinore McCance-Katz, M.D., Ph.D. Photo credit: SAMHSA

“We must do this now,” McCance-Katz stated. “We must not waste time continuing a program that has had since 1997 to show its effectiveness.”

A week later, the AAAP announced that it had received the multimillion-dollar grant to “lead the coalition of national professional organizations on the front lines of the opioid crisis in a state-based effort to expand the availability of treatment for opioid use … by providing training, educational resources and clinical mentoring for healthcare providers and community health centers across the country.”

‘The Way SAMHSA Does Business’

.

McCance-Katz followed up her January statement with a blog entry posted on SAMHSA’s website in late March. In it, she announced that she was cutting contracts to technical assistance providers that had helped the agency administer grants for decades.

“Changing the way SAMHSA does business — to be less reliant on an antiquated system that has depended on external contractors — will enable the agency to realize millions of dollars in savings,” she said. “These savings will be turned back to America’s communities through the funding of more grants to implement the much-needed programs and services for those living with mental and substance use disorders.”

Within hours of the blog’s posting, dozens of companies received notice that their contracts would be terminated, one contractor told WhoWhatWhy.

The Professional Services Council, a trade association that represents government contractors, is “troubled” by McCance-Katz’s decision, council spokeswoman Ashlei Stevens said in an email statement.

Billions are flowing out of Washington in the midst of a national crisis, and the disruption caused by sudden contracting changes could “harm SAMHSA’s ability to achieve its mission outcomes, and ultimately erode needed capabilities that support the agency’s important work and the millions of American families that depend on it,” Stevens wrote.

‘How Do We Rebuild Lives?’

.

For communities that have been ravaged by opioids, medicine alone isn’t the answer, said Natalie Andrews — a licensed clinical social worker in rural Illinois, where opioids are now responsible for more deaths than homicides and car crashes.

“This is a public health issue. It’s a public health epidemic,” Andrews said.

Andrews has lobbied for medicinal interventions and seen them work effectively. But opioids are tearing holes in the social fabric of small towns, and kicking addiction is merely one patch. Addicts often need job training — not to mention jobs — so it’s “not just rehabilitation and recovery” that need government focus, “it’s how do we rebuild lives?” Andrews said in an interview with WhoWhatWhy.

A Big Bet on a Small Group

.

Whatever the merits of the medical-versus-recovery argument, the new grants are a boon to the AAAP. The $24 million in opioid grants is nearly twice the total amount of grants the group received in the previous 15 years combined, an analysis of government records reveals.

According to the academy’s most recent tax return, the group handled fewer than $2 million in federal grants in 2016, disbursing about $800,000 to other organizations. Its payroll was around $622,000 and its highest salary went to Executive Director Kathryn Cates-Wessel, who was paid nearly $186,000 in 2016.

Kathryn Cates-Wessel

Kathryn Cates-Wessel, Chief Executive Officer at American Academy of Addiction Psychiatry (AAAP). Photo credit: SAMHSA / YouTube

Like McCance-Katz, Cates-Wessel lives in Rhode Island. The two also worked together on a planning committee at Brown University’s Office of Continuing Medical Education.

Cates-Wessel did not respond to requests seeking comment.

Three of the addiction academy’s four largest federal grants have been awarded while McCance-Katz was at SAMHSA, government records show.

‘No Accountability’

.

When Trump nominated McCance-Katz last year, few spoke out against her. One exception was a conservative Congressman, who might otherwise have been one of McCance-Katz’s staunchest defenders. Then-US Rep. Tim Murphy, a Republican from Pennsylvania, had co-authored the legislation that created McCance-Katz’s new job, had advocated for the medical model of mental health for years, and had been one of Trump’s most loyal backbenchers.

Yet McCance-Katz’s nomination “stunned” him, Murphy said at the time. He had seen her work in her previous government tour, as SAMHSA’s chief medical officer under President Barack Obama. During McCance-Katz’s tenure, he charged, the agency suffered from “questionable hiring practices,” and provided “no accountability for federal grants.” He even blamed McCance-Katz for the very approach she has skewered others for — “an anti-medical approach to serious mental illness and substance abuse treatment” contributing to “the continued upward rise of suicide and substance abuse deaths.”

Meanwhile, opioid casualties have continued to mount. Emergency room runs for opioid overdoses grew by 30 percent between July 2016 and September 2017, the most recent federal statistics show. The Midwest saw the biggest increase in overdoses, at 70 percent, but overdoses in big cities leapt by 54 percent over the same time, the government says.

Bill Myers lives and works in Washington. Email him at myers101@outlook.com. He tweets from @billcaphill.

Correction/Clarification (4/11/2018, 5:10 pm): A previous version of this story incorrectly stated that Elinore F. McCance-Katz was deputy secretary of Health and Human Services — she is deputy secretary of the sub-department of Mental Health and Substance Use. It also mischaracterized the scope of AAAP’s grant: AAAP is being hired as a technical adviser. We also removed a sentence that stated that she had “heaped scorn” on a particular mental health recovery model. After this article was published, SAMHSA sought to make the following clarification: “For the $12 million-per-year contract opportunity, SAMHSA had only two applicants: AAAP and ASAM (the American Society of Addiction Medicine). Dr. McCance-Katz is a member of both industry organizations. As stated to Bill Myers, she declined to meet with either organization, in order to avoid a conflict or the appearance of a conflict.”


Related front page panorama photo credit: Adapted by WhoWhatWhy from Donald Trump (The White House).

Where else do you see journalism of this quality and value?

Please help us do more. Make a tax-deductible contribution now.

Our Comment Policy

Keep it civilized, keep it relevant, keep it clear, keep it short. Please do not post links or promotional material. We reserve the right to edit and to delete comments where necessary.

print

5 responses to “Group With Ties to Trump Opioid Chief Scores Big”

  1. seco says:

    I’m not sure disgraced former representative Tim Murphy, himself in the pockets of PHARMA, a guy who is a staunch anti-abortionist but who forced the woman he had an affair with to have an abortion while espousing family values and whose office work environment was called a “Reign of Terror” – is the best person to cite as a critic of Trump, but that aside;

    McCance-Katz pushes the “medical model” because this administration is not interested in recovery long-term if they can sell you something and call you sober short-term or in lieu of that put you in jail and test you for years until you’re declared sober by a court.

    For example, the Trump administration is currently making an active push in supporting the use and adoption of a single anti-opioid addiction medicine by the courts, prisons, military, VA, federal employees, doctors, hospitals etc.

    Approved by the FDA in 2010 and based only on one trial in Russia, the drug called Vivitrol costs at least $1000 per use and must be used – at least 12 times- for the course of one year.

    It is favored by Trump over “recovery-based” models because it can be mandated and forced by courts on to offenders/patients, but precisely because of this quantitative, numbers based approach -rather than a qualitative life-style based program- more patients are relapsing and dying after they stop treatment.

    In other words, Trump cronies are making money off of patients who are dying despite treatment and this course of treatment is being forced on offenders by courts.

    Another example of self-dealing is Jeff Sessions’ choice for advisor on marijuana policy, Robert L. DuPont, former drug czar under Nixon, who last year in an article connected pot smoking directly to heroin use and pot legalization directly to the opioids epidemic.

    Dupont, also a favorite of Mike Pence, makes his money by selling drug testing kits to companies and governments and wants to make drug testing as common and routine as testing for cholesterol or diabetes.

    He has advocated for doctors to have the power to mandatory test their patients and to compel them into treatment against their will with a mandatory 5 year post-treatment monitoring period via random drug testing.

    The Trump administration’s regressive and revanchist corporate agenda prioritizes products over people and continues the same American Carnage which many of its supporters wished to end.

  2. andrew o says:

    $186k/year is not bad for an ex. Banks gave bigger BONUSES for much less. If they can get this to work then it would be wonderful.

    A real solution is a combo of both medical and recovery. Get the patent stable first then let the community support work with these people. Same is happening in cancer treatment. Dr Andrew Wiel has been using medical with holistic means at Arizona cancer centers and the results are far superior than the single bullet method.

  3. seco says:

    Today, the Surgeon General of the United States, Dr. Jerome Adams, a former member of Mike Pence administration in Indiana, issued a national advisory regarding Naloxone, which is the generic version of Vivitrol.

    Naloxone is a generic drug and costs less than $25 per vial in the US (even less in the rest of the world of course where it costs between $0.50 and $5.30 per dose).

    So how do you make money off of a cheap generic drug? you create an artificial scarcity and then jack up prices on your medical injecting devices.

    The scarcity is artificial because of lobbying efforts by the pharma companies such as Alkermes which owns Vivitrol and is further made acute by statements from people like the Surgeon General of the United States.

    According to the New England Journal of Medicine, the number of states with at least one law expanding access to naloxone increased from 8 in 2012 to 46 in 2016.

    Much like the Mylan epipen scandal last year and the Shkreli Pharma Bro scandal, Alkermes and other manufacturers of medical devices pushed for the adoption of its naloxone injectors by schools, police departments, hospitals, courts and prisons among others.

    This created an artificial scarcity of a once freely available drug. Doctors across the country are having a difficult time accessing the drug.

    Dr. Leana Wen, the health commissioner in Baltimore, said:

    “The federal government needs to follow their policy guidance with specific actions to actually ensure access.”

    She added, “We should not be priced out of the ability to save lives.”

    According to the NEJM study, the price for a package of two naloxone auto-injectors in the US, increased from $690 in 2014 to $4,500 in 2016.

    From the NEJM report: “When governments promote naloxone use, they have a responsibility to ensure the drug’s affordability”.

    Many of Trump’s base of voters are caught in this elite made supply-chain nightmare of American Carnage, which chews out workers and once their bodies are used up they are then milked like a cow for the rest of their lives in the for-profit so called healthcare system.

    Sadly their suffering will never end until quarterly earnings are made on the NASDAQ and commensurate bonuses are awarded to those least needy of such largesse.

    Or until they stop voting against their own self-interests.

  4. C says:

    186k a year for the director of a nonprofit actually trying to benefit society is POCKET CHANGE compared to Trump aides/cabinet members. This article is incredibly misleading and draws way more conclusions than the facts provide.

    You might be considered a more reliable source if you didn’t try to stir the pot with an org that has had the same mission since pre-Trump days. My advice…focus your energy elsewhere. This is an org that has been trying to fight the opioid crisis for 10+ years, before Trump attempted to make it a “national emergency”.

  5. seco says:

    I think the point of the article is that the AAAP uses a medical model approach , which is simplistic and benefits corporations and rentiers rather than patients’ long term well being.

    Also, 186K is a a lot of money, especially when you put it in context of her organization getting $2million in federal money for 2016, disbursed about 40% of that to to “other” organizations – rather than producing programs themselves where they can track patient outcomes- then they paid out 75% of what they paid out, as salaries in the amount of $622K, a whopping 30% of which went to her at 186K or about 10% commission on the total take.

    Pretty good gig if you can get it; I’m sure she sleeps good at night knowing she is helping people..